Tessera targets 2027 revenue of $14-16M and ~$30M by 2029, implying ~40% CAGR

BiomX Inc.

Initial 2027 revenue target of $14M-$16M, weighted to H2 2026 platform deployments; 2028 target ~$21M and 2029 target ~$30M.
2027 target build: $7M from backlog/signed contracts/purchase orders, $5M from existing-customer expansion, $3M from new customers.
2027 milestones: 70 platform deployments, 60 new customers, 15 expansion projects, 3 new geographies, 2 new verticals, 16 integrator/channel relationships.
Targets ~$7-8M (50% of 2027 revenue) from recurring software, licensing, service and support; ~$14M backlog expected by year-end 2027.
Growth plan combines organic expansion of the Tessera platform (Zorronet, DFSL subsidiaries) with selective future acquisitions; excludes companies under unexercised acquisition options.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.